<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We recently reported that <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>) and minimal disseminated disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDD</z:e>), assessed by long-distance PCR (LD-PCR) for t(8;14), are negative prognostic factors in mature B-cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) and in Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>However, t(8;14) is detectable in only about 70% of patients, thus preventing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> studies by this approach in the remaining patients </plain></SENT>
<SENT sid="2" pm="."><plain>At present, no molecular assays have been reported for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDD</z:e> analysis in t(8;14)-negative patients </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of our study was to evaluate the characteristics of patient-specific immunoglobulin (Ig) gene rearrangements as RQ-PCR targets for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> analysis, in order to extend <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> studies to those patients who are not eligible for the LD-PCR assay </plain></SENT>
<SENT sid="4" pm="."><plain>The study was performed according to the guidelines of the European Study Group on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> detection in ALL (ESG-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>-ALL) </plain></SENT>
<SENT sid="5" pm="."><plain>Overall, 36 B-ALL and 19 BL cases were analyzed </plain></SENT>
<SENT sid="6" pm="."><plain>Multiple PCR reactions were performed for each sample to identify heavy and kappa light-chain rearrangements </plain></SENT>
<SENT sid="7" pm="."><plain>A total of 97 RQ-PCR targets (62 for <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>, 35 for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) were analyzed for sensitivity </plain></SENT>
<SENT sid="8" pm="."><plain>The rearrangement pattern identified was similar to that reported for <z:mpath ids='MPATH_458'>normal</z:mpath> peripheral blood lymphocytes </plain></SENT>
<SENT sid="9" pm="."><plain>In 88% of the targets, a sensitivity of at least 10(-4) was achieved </plain></SENT>
<SENT sid="10" pm="."><plain>In 87% of patients (84% of <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALLs</z:e>, 95% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e>) at least one sensitive target was available </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> PCR targets identified at diagnosis were preserved at relapse </plain></SENT>
<SENT sid="12" pm="."><plain>Our results suggest that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDD</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> can be successfully studied using a single sensitive Ig target in the great majority of <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cases </plain></SENT>
<SENT sid="13" pm="."><plain>The combination of LD-PCR and Ig-based assays will allow <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> analysis in virtually <z:hpo ids='HP_0000001'>all</z:hpo> of the patients </plain></SENT>
</text></document>